Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ROAD - Real-World Outcomes of Darolutamide, ADT, With or Without Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer

NCT07344779 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT07344779
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07344779 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ROAD - Real-World Outcomes of Darolutamide, ADT, With or Without Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
Lead sponsor
Bayer
Phase
Observational
Overall status
Active, not recruiting
Start date
January 29, 2026
Completion date
June 30, 2030
Enrollment
1,600 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic hormone-sensitive prostate cancer